Shares of Qingsong Health (02661) experienced a significant surge in morning trading, rising nearly 45% at one point.

As of the latest update, the stock was up 33.19% to HK$24.04, with a trading volume reaching HK$520 million.

The rally follows news that the company's evidence-based medical AI product, "Zhengyuanfang," has been officially integrated into its service platform for doctors and medical professionals, "Yilu Qingsong."

In addition, the company has been actively securing strategic partnerships.

It has formally signed a comprehensive cooperation agreement with Hubei Chinese Online to jointly build an authoritative and traceable medical data foundation.

A strategic partnership has also been established with the high-end comprehensive medical service brand "Yihe Ni" to jointly launch a premium family membership health management plan covering the entire cycle of prevention, diagnosis, treatment, and rehabilitation.

Public data indicates that as of March 31, 2026, the number of medical professional users on the "Yilu Qingsong" platform, empowered by "Zhengyuanfang," reached 69,615, representing a year-on-year increase of 46.4%.

Among these users, 36,678 were associate chief physicians or higher, accounting for approximately 52.7% of the total and marking a 42.7% year-on-year growth.

The platform also had 3,672 ophthalmology professionals, a surge of 171.0% compared to the previous year.

The company has established a three-tier AI framework comprising the "Stellar Cloud Digital Base," the "Dr.GPT vertical medical large model," and the "Zhengyuanfang series of evidence-based medical intelligent agents."